Business Daily Media

Men's Weekly

.

Anticancer Agent Tazverik Tablets 200mg (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma

  • Written by ACN Newswire - Press Releases

Anticancer Agent Tazverik Tablets 200mg (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma

TOKYO, Aug 16, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched the anticancer agent EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide), in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable). Eisai

Read more //?#

AIIMS Group and AdVisible merge

Two of Australia’s most established independent agencies unite, creating marketing powerhouse backed by three decades of combined experience     ...

Block's layoffs are a design win. Here's why

We spend millions designing features that save users 30 seconds. Block just saved thousands of employees 40 hours a week. That's not a crisis. That's...

Why I Decided to Build a Better Way to Build Homes

Why does building a home still feel like stepping into the unknown? In an industry where costs blow out and decisions come too late, certainty has...

Leonardo.Ai reveals new brand, expanding its creator-first platform for the next era of generative AI

The company has also launched its developer API to empower creators and builders to integrate AI into their workflows SYDNEY, Australia – 19 Febr...

Psychosocial injury risk starts inside workplace microcultures

Psychological injury is now one of the most expensive categories of workers compensation claims in Australia, with Safe Work Australia reporting t...

2025 Thryv Business and Consumer Report - Australian small businesses show grit under pressure

Australia’s small businesses are powering ahead with optimism, resilience and discipline, however, mounting pressures on costs, wellbeing and cons...